Close Menu

MediChem CEO Mike Flavin prefers to call it a merger. With the estimated 29 percent premium DeCode Genetics paid in its $84 million acquisition of MediChem, Flavin can pretty much call it whatever he wants.

The first whispers of an acquisition came last November, after many discussions about how the two companies could best work together, Flavin says. “The most optimal way for us to proceed was to come together. We really wanted to effect this one-plus-one-equals five equation.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.